FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382600481> ?p ?o ?g. }

• W4382600481 endingPage "2759" @default.
• W4382600481 startingPage "2747" @default.
• W4382600481 abstract "A design has been established for the surface decoration of superparamagnetic iron oxide nanoparticles (SPIONs) with anti-vascular endothelial growth factor peptide, HRH, to formulate a targeted paclitaxel (PTX) delivery nanosystem with notable tumor targetability and antiangiogenic activity. The design methodology included (i) tandem surface functionalization via coupling reactions, (ii) pertinent physicochemical characterization, (iii) in vitro assessment of drug release, anti-proliferative activity, and quantification of vascular endothelial growth factor A (VEGF-A) levels, and (iv) in vivo testing using a lung tumor xenograft mouse model. Formulated CLA-coated PTX-SPIONs@HRH depicted a size and surface charge of 108.5 ± 3.5 nm and -30.4 ± 2.3 mV, respectively, and a quasi-spherical shape relative to pristine SPIONs. Fourier transform infrared (FTIR) analysis and estimation of free carboxylic groups supported the preparation of the CLA-coated PTX-SPIONs@HRH. CLA-coated PTX-SPIONs@HRH exhibited high PTX loading efficiency (98.5%) and sustained release in vitro, with a marked dose dependent anti-proliferative activity in A549 lung adenocarcinoma cells, complimented by an enhanced cellular uptake. CLA-coated PTX-SPIONs@HRH significantly reduced secretion levels of VEGF-A in human dermal microvascular endothelial cells from 46.9 to 35.6 pg/mL compared to untreated control. A 76.6% tumor regression was recorded in a lung tumor xenograft mouse model following intervention with CLA-coated PTX-SPIONs@HRH, demonstrating tumor targetability and angiogenesis inhibition. CLA-coated PTX-SPIONs@HRH enhanced the half-life of PTX by almost 2-folds and demonstrated a prolonged PTX plasma circulation time from a subcutaneous injection (SC). Thus, it is suggested that CLA-coated PTX-SPIONs@HRH could provide a potential effective treatment modality for non-small-cell lung carcinoma as a nanomedicine." @default.
• W4382600481 created "2023-06-30" @default.
• W4382600481 creator A5003185613 @default.
• W4382600481 creator A5023164091 @default.
• W4382600481 creator A5042929695 @default.
• W4382600481 creator A5067328344 @default.
• W4382600481 creator A5067881395 @default.
• W4382600481 creator A5076877003 @default.
• W4382600481 date "2023-06-29" @default.
• W4382600481 modified "2023-10-14" @default.
• W4382600481 title "Surface Immobilization of Anti-VEGF Peptide on SPIONs for Antiangiogenic and Targeted Delivery of Paclitaxel in Non-Small-Cell Lung Carcinoma" @default.
• W4382600481 cites W1946451131 @default.
• W4382600481 cites W1968504912 @default.
• W4382600481 cites W1977864607 @default.
• W4382600481 cites W1980568044 @default.
• W4382600481 cites W1989392234 @default.
• W4382600481 cites W2048136402 @default.
• W4382600481 cites W2061697681 @default.
• W4382600481 cites W2070868743 @default.
• W4382600481 cites W2104077798 @default.
• W4382600481 cites W2121929569 @default.
• W4382600481 cites W2138787512 @default.
• W4382600481 cites W2141171507 @default.
• W4382600481 cites W2145706118 @default.
• W4382600481 cites W2155837541 @default.
• W4382600481 cites W2281496323 @default.
• W4382600481 cites W2308784976 @default.
• W4382600481 cites W2514059345 @default.
• W4382600481 cites W2564323819 @default.
• W4382600481 cites W2580702738 @default.
• W4382600481 cites W2592112618 @default.
• W4382600481 cites W2592835078 @default.
• W4382600481 cites W2613322785 @default.
• W4382600481 cites W2626864974 @default.
• W4382600481 cites W2793649507 @default.
• W4382600481 cites W2793943975 @default.
• W4382600481 cites W2806376679 @default.
• W4382600481 cites W2807410315 @default.
• W4382600481 cites W2883052264 @default.
• W4382600481 cites W2897796189 @default.
• W4382600481 cites W2901436427 @default.
• W4382600481 cites W2904685405 @default.
• W4382600481 cites W2959497269 @default.
• W4382600481 cites W2973326705 @default.
• W4382600481 cites W2983881420 @default.
• W4382600481 cites W2987630388 @default.
• W4382600481 cites W2994642443 @default.
• W4382600481 cites W3006780872 @default.
• W4382600481 cites W3011520922 @default.
• W4382600481 cites W3015915882 @default.
• W4382600481 cites W3017060188 @default.
• W4382600481 cites W3030306928 @default.
• W4382600481 cites W3034361437 @default.
• W4382600481 cites W3108583367 @default.
• W4382600481 cites W3124682599 @default.
• W4382600481 cites W3127357456 @default.
• W4382600481 cites W3131842642 @default.
• W4382600481 cites W3133421834 @default.
• W4382600481 cites W3135793034 @default.
• W4382600481 cites W3161627570 @default.
• W4382600481 cites W3182198048 @default.
• W4382600481 cites W3184030384 @default.
• W4382600481 cites W3195423066 @default.
• W4382600481 cites W3203381395 @default.
• W4382600481 cites W4206124759 @default.
• W4382600481 cites W4214719171 @default.
• W4382600481 cites W4220995729 @default.
• W4382600481 cites W4223476004 @default.
• W4382600481 cites W4229449474 @default.
• W4382600481 cites W4230947778 @default.
• W4382600481 cites W4282821993 @default.
• W4382600481 cites W4301392186 @default.
• W4382600481 doi "https://doi.org/10.1021/acsabm.3c00224" @default.
• W4382600481 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37384895" @default.
• W4382600481 hasPublicationYear "2023" @default.
• W4382600481 type Work @default.
• W4382600481 citedByCount "0" @default.
• W4382600481 crossrefType "journal-article" @default.
• W4382600481 hasAuthorship W4382600481A5003185613 @default.
• W4382600481 hasAuthorship W4382600481A5023164091 @default.
• W4382600481 hasAuthorship W4382600481A5042929695 @default.
• W4382600481 hasAuthorship W4382600481A5067328344 @default.
• W4382600481 hasAuthorship W4382600481A5067881395 @default.
• W4382600481 hasAuthorship W4382600481A5076877003 @default.
• W4382600481 hasBestOaLocation W43826004811 @default.
• W4382600481 hasConcept C126322002 @default.
• W4382600481 hasConcept C150903083 @default.
• W4382600481 hasConcept C167734588 @default.
• W4382600481 hasConcept C178790620 @default.
• W4382600481 hasConcept C185592680 @default.
• W4382600481 hasConcept C202751555 @default.
• W4382600481 hasConcept C207001950 @default.
• W4382600481 hasConcept C2776694085 @default.
• W4382600481 hasConcept C2777025900 @default.
• W4382600481 hasConcept C2777292972 @default.
• W4382600481 hasConcept C2779820397 @default.
• W4382600481 hasConcept C2780394083 @default.
• W4382600481 hasConcept C502942594 @default.

• next